Clinical Trial Update: Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With AD [Phase 4]

View source ↗

Summary

Phase 4 trial assessing how FBB PET amyloid imaging changes diagnosis in Alzheimer's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Flutemetamol F18 (FBB) PET imaging (fluorine-18-labeled flutemetamol)

Snippet

Sponsor: Piramal Imaging Limited | Conditions: Alzheimer's Disease (AD) | Phase 4 | Status: COMPLETED | Results posted: 2018-11-02